BIOCOGNON LLC

Biotech · Private

Nanobody discovery platform using self-reporting yeast dual biosensor technology for antibody screening and design

Grants
$577K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I:Combinatorial Platform for the Discovery of Improved Molecular Recognition Components for Use in Therapeutic and Diagnostic Antibodies$273,550
Federal grantDepartment of Health and Human Services · Phase I · Combinatorial pipeline for discovery of anti-GPCR Nanobodies$303,024
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2880Sophia Bioscience Inc——
2881CG Oncology——
2882LABORECOM THERAPEUTICS INC.——
2883BIOCOGNON LLC——
2884MYOLOGICA, LLC——
2885JANUSQ, LLC——
2886FEMTOFLUIDICS INCORPORATED——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.